Cayman
Showing 28651–28800 of 45550 results
-
MBZP is a derivative of benzylpiperazine, a Schedule I designer drug that has been shown to have a mixed mechanism of action, acting on both serotonergic and dopaminergic receptor systems in a similar fashion to MDMA.{21246,21444,20498} This product is intended for research and forensic purposes.
Brand:CaymanSKU:11736 - 100 mgAvailable on backorder
MBZP is a derivative of benzylpiperazine, a Schedule I designer drug that has been shown to have a mixed mechanism of action, acting on both serotonergic and dopaminergic receptor systems in a similar fashion to MDMA.{21246,21444,20498} This product is intended for research and forensic purposes.
Brand:CaymanSKU:11736 - 50 mgAvailable on backorder
While class I HDACs are localized predominantly within the nucleus, class II HDACs shuttle into and out of the nucleus in response to intracellular signaling.{26846} Class IIa HDACs, which includes HDAC4, 5, 7, and 9, commonly act as corepressors and play diverse roles in cell biology.{22864} MC 1568 is a selective inhibitor of class IIa HDACs, with greater than 170-fold selectivity over class I HDACs, including HDAC1.{26834,26835,26837} It has been used in cells (1-10 µM) and in mice to elucidate the roles of class IIa HDACs in cell proliferation and differentiation, apoptosis, myogenesis, adipogenesis, and fibrosis.{26837,26840,19753,26839,26836,26838}
Brand:CaymanSKU:- While class I HDACs are localized predominantly within the nucleus, class II HDACs shuttle into and out of the nucleus in response to intracellular signaling.{26846} Class IIa HDACs, which includes HDAC4, 5, 7, and 9, commonly act as corepressors and play diverse roles in cell biology.{22864} MC 1568 is a selective inhibitor of class IIa HDACs, with greater than 170-fold selectivity over class I HDACs, including HDAC1.{26834,26835,26837} It has been used in cells (1-10 µM) and in mice to elucidate the roles of class IIa HDACs in cell proliferation and differentiation, apoptosis, myogenesis, adipogenesis, and fibrosis.{26837,26840,19753,26839,26836,26838}
Brand:CaymanSKU:- While class I HDACs are localized predominantly within the nucleus, class II HDACs shuttle into and out of the nucleus in response to intracellular signaling.{26846} Class IIa HDACs, which includes HDAC4, 5, 7, and 9, commonly act as corepressors and play diverse roles in cell biology.{22864} MC 1568 is a selective inhibitor of class IIa HDACs, with greater than 170-fold selectivity over class I HDACs, including HDAC1.{26834,26835,26837} It has been used in cells (1-10 µM) and in mice to elucidate the roles of class IIa HDACs in cell proliferation and differentiation, apoptosis, myogenesis, adipogenesis, and fibrosis.{26837,26840,19753,26839,26836,26838}
Brand:CaymanSKU:- While class I HDACs are localized predominantly within the nucleus, class II HDACs shuttle into and out of the nucleus in response to intracellular signaling.{26846} Class IIa HDACs, which includes HDAC4, 5, 7, and 9, commonly act as corepressors and play diverse roles in cell biology.{22864} MC 1568 is a selective inhibitor of class IIa HDACs, with greater than 170-fold selectivity over class I HDACs, including HDAC1.{26834,26835,26837} It has been used in cells (1-10 µM) and in mice to elucidate the roles of class IIa HDACs in cell proliferation and differentiation, apoptosis, myogenesis, adipogenesis, and fibrosis.{26837,26840,19753,26839,26836,26838}
Brand:CaymanSKU:-
Mc-Val-Cit-PAB is a peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs).{45295} It contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-aminobenzyl (PAB) spacer that allows the peptide to be linked to active compounds, such as anticancer agents. Mc-Val-Cit-PAB is cleaved in vivo by cathepsin B, a protease highly expressed in cancer cells, which confers specificity of the ADC to cancer cells. Upon cleavage by cathepsin B, the active compound is released at the target site. Mc-Val-Cit-PAB has been used in the synthesis of an ADC containing the tubulin polymerization inhibitor KGP05. It has also been used as a precursor in the synthesis of Mc-Val-Cit-PABC-PNP (Item No. 23881).{45296}
Brand:CaymanSKU:28285 - 1 mgAvailable on backorder
Mc-Val-Cit-PAB is a peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs).{45295} It contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-aminobenzyl (PAB) spacer that allows the peptide to be linked to active compounds, such as anticancer agents. Mc-Val-Cit-PAB is cleaved in vivo by cathepsin B, a protease highly expressed in cancer cells, which confers specificity of the ADC to cancer cells. Upon cleavage by cathepsin B, the active compound is released at the target site. Mc-Val-Cit-PAB has been used in the synthesis of an ADC containing the tubulin polymerization inhibitor KGP05. It has also been used as a precursor in the synthesis of Mc-Val-Cit-PABC-PNP (Item No. 23881).{45296}
Brand:CaymanSKU:28285 - 10 mgAvailable on backorder
Mc-Val-Cit-PAB is a peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs).{45295} It contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-aminobenzyl (PAB) spacer that allows the peptide to be linked to active compounds, such as anticancer agents. Mc-Val-Cit-PAB is cleaved in vivo by cathepsin B, a protease highly expressed in cancer cells, which confers specificity of the ADC to cancer cells. Upon cleavage by cathepsin B, the active compound is released at the target site. Mc-Val-Cit-PAB has been used in the synthesis of an ADC containing the tubulin polymerization inhibitor KGP05. It has also been used as a precursor in the synthesis of Mc-Val-Cit-PABC-PNP (Item No. 23881).{45296}
Brand:CaymanSKU:28285 - 5 mgAvailable on backorder
Mc-Val-Cit-PAB is a peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs).{45295} It contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-aminobenzyl (PAB) spacer that allows the peptide to be linked to active compounds, such as anticancer agents. Mc-Val-Cit-PAB is cleaved in vivo by cathepsin B, a protease highly expressed in cancer cells, which confers specificity of the ADC to cancer cells. Upon cleavage by cathepsin B, the active compound is released at the target site. Mc-Val-Cit-PAB has been used in the synthesis of an ADC containing the tubulin polymerization inhibitor KGP05. It has also been used as a precursor in the synthesis of Mc-Val-Cit-PABC-PNP (Item No. 23881).{45296}
Brand:CaymanSKU:28285 - 50 mgAvailable on backorder
Mc-Val-Cit-PABC-PNP is a peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs).{37316} It contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-nitrophenol (PNP) group that allows the peptide to be linked to anticancer compounds, such as doxorubicin (Item No. 15007) or monomethyl auristatin E (MMAE; Item No. 16267).{37316,37315} ADCs target specific cell populations to induce a selective response, such as cell death in cancer cells.
Brand:CaymanSKU:23881 - 1 mgAvailable on backorder
Mc-Val-Cit-PABC-PNP is a peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs).{37316} It contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-nitrophenol (PNP) group that allows the peptide to be linked to anticancer compounds, such as doxorubicin (Item No. 15007) or monomethyl auristatin E (MMAE; Item No. 16267).{37316,37315} ADCs target specific cell populations to induce a selective response, such as cell death in cancer cells.
Brand:CaymanSKU:23881 - 10 mgAvailable on backorder
Mc-Val-Cit-PABC-PNP is a peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs).{37316} It contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-nitrophenol (PNP) group that allows the peptide to be linked to anticancer compounds, such as doxorubicin (Item No. 15007) or monomethyl auristatin E (MMAE; Item No. 16267).{37316,37315} ADCs target specific cell populations to induce a selective response, such as cell death in cancer cells.
Brand:CaymanSKU:23881 - 5 mgAvailable on backorder
MC1742 is an inhibitor of class I histone deacetylases (HDACs; IC50s = 0.1, 0.11, 0.02, and 0.61 μM for HDAC1, -2, -3, and -8, respectively) and class IIb HDACs (IC50s = 7 and 40 nM for HDAC6 and HDAC10, respectively).{48634} It is selective for class I and class IIb over class IIa HDACs (IC50s = >50 μM for HDAC4, -5, -7, and -9). MC1742 reduces proliferation of HOS, MG-63, RD, A204, SK-ES-1, and A673 sarcoma cancer stem cells (CSCs). It increases levels of acetylated histone H3 and acetylated tubulin and induces apoptosis in MG-63 CSCs when used at a concentration of 2 μM. MC1742 also reactivates HIV-1 in JLAT 10.6 latently infected cells (EC50 = 350 nM).{48635}
Brand:CaymanSKU:29171 - 1 mgAvailable on backorder
MC1742 is an inhibitor of class I histone deacetylases (HDACs; IC50s = 0.1, 0.11, 0.02, and 0.61 μM for HDAC1, -2, -3, and -8, respectively) and class IIb HDACs (IC50s = 7 and 40 nM for HDAC6 and HDAC10, respectively).{48634} It is selective for class I and class IIb over class IIa HDACs (IC50s = >50 μM for HDAC4, -5, -7, and -9). MC1742 reduces proliferation of HOS, MG-63, RD, A204, SK-ES-1, and A673 sarcoma cancer stem cells (CSCs). It increases levels of acetylated histone H3 and acetylated tubulin and induces apoptosis in MG-63 CSCs when used at a concentration of 2 μM. MC1742 also reactivates HIV-1 in JLAT 10.6 latently infected cells (EC50 = 350 nM).{48635}
Brand:CaymanSKU:29171 - 10 mgAvailable on backorder
MC1742 is an inhibitor of class I histone deacetylases (HDACs; IC50s = 0.1, 0.11, 0.02, and 0.61 μM for HDAC1, -2, -3, and -8, respectively) and class IIb HDACs (IC50s = 7 and 40 nM for HDAC6 and HDAC10, respectively).{48634} It is selective for class I and class IIb over class IIa HDACs (IC50s = >50 μM for HDAC4, -5, -7, and -9). MC1742 reduces proliferation of HOS, MG-63, RD, A204, SK-ES-1, and A673 sarcoma cancer stem cells (CSCs). It increases levels of acetylated histone H3 and acetylated tubulin and induces apoptosis in MG-63 CSCs when used at a concentration of 2 μM. MC1742 also reactivates HIV-1 in JLAT 10.6 latently infected cells (EC50 = 350 nM).{48635}
Brand:CaymanSKU:29171 - 5 mgAvailable on backorder
![A P-gp inhibitor; inhibits the efflux of [3H]vinblastine by ABCB1 in Caco-2 colon cancer cells (EC50 = 0.05 µM); inhibits the efflux of rhodamine-123 and calcein-AM by BCRP and MRP1 in MDCK cells (EC50s = 73 and 9.3 µM](https://interpriseusa.com/wp-content/uploads/2021/06/21330.png)
MC70 is a P-glycoprotein (P-gp) inhibitor.{45376} It inhibits the efflux of [3H]vinblastine by ATP binding cassette subfamily B member 1 (ABCB1) in Caco-2 colon cancer cells (EC50 = 0.05 µM). MC70 also inhibits the efflux of rhodamine-123 (Item No. 16672) and calcein-AM (Item No. 14948) by breast cancer resistant protein (BCRP) and multidrug resistance-associated protein 1 (MRP1) in MDCK cells (EC50s = 73 and 9.3 µM, respectively). MC70 (2 or 20 µM) enhances growth inhibition of adriamycin and doxorubicin-resistant (ADR) MCF-7/ADR breast cancer cells when used in combination with doxorubicin (Item No. 15007), but does not alter the effectiveness of doxorubicin on growth inhibition in Caco-2 cells.{45377} It increases phosphorylation of p38 and JNK in Caco-2 cells and MCF-7/ADR cells when used at a concentration of 20 µM.
Brand:CaymanSKU:21330 -Out of stock
MC70 is a P-glycoprotein (P-gp) inhibitor.{45376} It inhibits the efflux of [3H]vinblastine by ATP binding cassette subfamily B member 1 (ABCB1) in Caco-2 colon cancer cells (EC50 = 0.05 µM). MC70 also inhibits the efflux of rhodamine-123 (Item No. 16672) and calcein-AM (Item No. 14948) by breast cancer resistant protein (BCRP) and multidrug resistance-associated protein 1 (MRP1) in MDCK cells (EC50s = 73 and 9.3 µM, respectively). MC70 (2 or 20 µM) enhances growth inhibition of adriamycin and doxorubicin-resistant (ADR) MCF-7/ADR breast cancer cells when used in combination with doxorubicin (Item No. 15007), but does not alter the effectiveness of doxorubicin on growth inhibition in Caco-2 cells.{45377} It increases phosphorylation of p38 and JNK in Caco-2 cells and MCF-7/ADR cells when used at a concentration of 20 µM.
Brand:CaymanSKU:21330 -Out of stock
MC70 is a P-glycoprotein (P-gp) inhibitor.{45376} It inhibits the efflux of [3H]vinblastine by ATP binding cassette subfamily B member 1 (ABCB1) in Caco-2 colon cancer cells (EC50 = 0.05 µM). MC70 also inhibits the efflux of rhodamine-123 (Item No. 16672) and calcein-AM (Item No. 14948) by breast cancer resistant protein (BCRP) and multidrug resistance-associated protein 1 (MRP1) in MDCK cells (EC50s = 73 and 9.3 µM, respectively). MC70 (2 or 20 µM) enhances growth inhibition of adriamycin and doxorubicin-resistant (ADR) MCF-7/ADR breast cancer cells when used in combination with doxorubicin (Item No. 15007), but does not alter the effectiveness of doxorubicin on growth inhibition in Caco-2 cells.{45377} It increases phosphorylation of p38 and JNK in Caco-2 cells and MCF-7/ADR cells when used at a concentration of 20 µM.
Brand:CaymanSKU:21330 -Out of stock
MC70 is a P-glycoprotein (P-gp) inhibitor.{45376} It inhibits the efflux of [3H]vinblastine by ATP binding cassette subfamily B member 1 (ABCB1) in Caco-2 colon cancer cells (EC50 = 0.05 µM). MC70 also inhibits the efflux of rhodamine-123 (Item No. 16672) and calcein-AM (Item No. 14948) by breast cancer resistant protein (BCRP) and multidrug resistance-associated protein 1 (MRP1) in MDCK cells (EC50s = 73 and 9.3 µM, respectively). MC70 (2 or 20 µM) enhances growth inhibition of adriamycin and doxorubicin-resistant (ADR) MCF-7/ADR breast cancer cells when used in combination with doxorubicin (Item No. 15007), but does not alter the effectiveness of doxorubicin on growth inhibition in Caco-2 cells.{45377} It increases phosphorylation of p38 and JNK in Caco-2 cells and MCF-7/ADR cells when used at a concentration of 20 µM.
Brand:CaymanSKU:21330 -Out of stock
Mca-DEVDAP-K(Dnp)-OH is a substrate for caspase-3.{2549} Upon cleavage by caspase-3, 7-methoxycoumarin-4-acetyl (Mca) is released and its fluorescence can be used to quantify caspase-3 activity. Mca displays excitation/emission maxima of 328/420 nm, respectively.
Brand:CaymanSKU:24563 - 1 mgAvailable on backorder
Mca-DEVDAP-K(Dnp)-OH is a substrate for caspase-3.{2549} Upon cleavage by caspase-3, 7-methoxycoumarin-4-acetyl (Mca) is released and its fluorescence can be used to quantify caspase-3 activity. Mca displays excitation/emission maxima of 328/420 nm, respectively.
Brand:CaymanSKU:24563 - 500 µgAvailable on backorder
Mca-PL is a fluorogenic peptide that has been used as a building block in the synthesis of Mca-PLGL-Dpa-AR-NH2 (Item No. 24695), a fluorogenic substrate for matrix metalloproteinase-2 (MMP-2) and MMP-7.{39527}
Brand:CaymanSKU:24696 - 1 mgAvailable on backorder
Mca-PLAC(p-OMeBz)-WAR(Dpa)-NH2 is a fluorogenic substrate for matrix metalloproteinase-14 (MMP-14).{38800} Upon cleavage by MMP-14, 7-methoxycoumarin-4-acetyl (Mca) is released and its fluorescence can be used to quantify MMP activity. Mca displays excitation/emission maxima of 328/420 nm, respectively.
Brand:CaymanSKU:24703 - 1 mgAvailable on backorder
Mca-PLAC(p-OMeBz)-WAR(Dpa)-NH2 is a fluorogenic substrate for matrix metalloproteinase-14 (MMP-14).{38800} Upon cleavage by MMP-14, 7-methoxycoumarin-4-acetyl (Mca) is released and its fluorescence can be used to quantify MMP activity. Mca displays excitation/emission maxima of 328/420 nm, respectively.
Brand:CaymanSKU:24703 - 500 µgAvailable on backorder
Immunogen: Full length human recombinant MCAD • Host: Rabbit • Species Reactivity: (+) Human, mouse, ovine, porcine MCAD; other species not tested • Application(s): WB; other applications not tested • MCAD is a mitochondrial enzyme that catalyzes the first step in the β-oxidation of fatty acids. Its expression is induced during periods of fasting and is regulated by PPARα, a ligand-activated transcription factor involved in the regulation of lipid homeostasis. MCAD expression can be used as a marker to evaluate the in vivo activity of PPARα.
Brand:CaymanSKU:101730- 500 µl Medium-chain fatty acyl-CoA dehydrogenase (MCAD) is a mitochondrial enzyme that catalyzes the first step in the βoxidation of fatty acids. MCAD expression is induced during periods of fasting, when reliance on fatty acids for energy is increased.{7572,7416} The promoter for MCAD contains a peroxisome proliferator response element (PPRE) and is regulated transcriptionally by peroxisome proliferator-activated receptor alpha (PPARα), a ligand-activated transcription factor involved in the regulation of lipid homeostasis.{7572,7571,4136} Because of this, MCAD expression can be used as a marker to evaluate the in vivo activity of PPARα.{7572,7416} Human MCAD is approximately 87% homologous to porcine and rat MCAD, respectively.{7568,7570} MCAD is expressed in liver, heart, kidney, and skeletal muscle.
Brand:CaymanSKU:101730 - 500 µlAvailable on backorder
Immunogen: Full length human recombinant MCAD • Host: Rabbit • Species Reactivity: (+) Human, mouse, ovine, porcine MCAD; other species not tested • Application(s): WB; other applications not tested • MCAD is a mitochondrial enzyme that catalyzes the first step in the β-oxidation of fatty acids. Its expression is induced during periods of fasting and is regulated by PPARα, a ligand-activated transcription factor involved in the regulation of lipid homeostasis. MCAD expression can be used as a marker to evaluate the in vivo activity of PPARα.
Brand:CaymanSKU:101730- 500 µlAvailable on backorder
The p160 steroid receptor coactivator (SRC) family, SRC-1/NCOA1, SRC-2/NCOA2/TIF2/GRIP1, and SRC-3/NCOA3/AIB1/RAC3/ACTR/pCIP, interact with nuclear receptors and other transcription factors to drive target gene expression and integrate growth signaling pathways on which cancer cells rely. MCB-613 is a small molecule stimulator of SRC-1, SRC-2, and SRC-3 that has been used to disrupt cancer cell homeostatic dependence on SRCs.{29318} MCB-613 can increase the interaction of SRCs with the coactivators CBP and CARM1 and can induce ER stress coupled to the generation of reactive oxygen species.{29318} Overactivation of SRCs by 1-7 µM MCB-613 was shown to selectively and dose dependently induce paraptosis in a variety of cancer cells in vitro but not in normal cells.{29318} At 20 mg/kg, MCB-613 was also shown to inhibit tumor growth in an MCF-7 breast cancer xenograft model in mice.{29318}
Brand:CaymanSKU:-Available on backorder
The p160 steroid receptor coactivator (SRC) family, SRC-1/NCOA1, SRC-2/NCOA2/TIF2/GRIP1, and SRC-3/NCOA3/AIB1/RAC3/ACTR/pCIP, interact with nuclear receptors and other transcription factors to drive target gene expression and integrate growth signaling pathways on which cancer cells rely. MCB-613 is a small molecule stimulator of SRC-1, SRC-2, and SRC-3 that has been used to disrupt cancer cell homeostatic dependence on SRCs.{29318} MCB-613 can increase the interaction of SRCs with the coactivators CBP and CARM1 and can induce ER stress coupled to the generation of reactive oxygen species.{29318} Overactivation of SRCs by 1-7 µM MCB-613 was shown to selectively and dose dependently induce paraptosis in a variety of cancer cells in vitro but not in normal cells.{29318} At 20 mg/kg, MCB-613 was also shown to inhibit tumor growth in an MCF-7 breast cancer xenograft model in mice.{29318}
Brand:CaymanSKU:-Available on backorder
The p160 steroid receptor coactivator (SRC) family, SRC-1/NCOA1, SRC-2/NCOA2/TIF2/GRIP1, and SRC-3/NCOA3/AIB1/RAC3/ACTR/pCIP, interact with nuclear receptors and other transcription factors to drive target gene expression and integrate growth signaling pathways on which cancer cells rely. MCB-613 is a small molecule stimulator of SRC-1, SRC-2, and SRC-3 that has been used to disrupt cancer cell homeostatic dependence on SRCs.{29318} MCB-613 can increase the interaction of SRCs with the coactivators CBP and CARM1 and can induce ER stress coupled to the generation of reactive oxygen species.{29318} Overactivation of SRCs by 1-7 µM MCB-613 was shown to selectively and dose dependently induce paraptosis in a variety of cancer cells in vitro but not in normal cells.{29318} At 20 mg/kg, MCB-613 was also shown to inhibit tumor growth in an MCF-7 breast cancer xenograft model in mice.{29318}
Brand:CaymanSKU:-Available on backorder
The p160 steroid receptor coactivator (SRC) family, SRC-1/NCOA1, SRC-2/NCOA2/TIF2/GRIP1, and SRC-3/NCOA3/AIB1/RAC3/ACTR/pCIP, interact with nuclear receptors and other transcription factors to drive target gene expression and integrate growth signaling pathways on which cancer cells rely. MCB-613 is a small molecule stimulator of SRC-1, SRC-2, and SRC-3 that has been used to disrupt cancer cell homeostatic dependence on SRCs.{29318} MCB-613 can increase the interaction of SRCs with the coactivators CBP and CARM1 and can induce ER stress coupled to the generation of reactive oxygen species.{29318} Overactivation of SRCs by 1-7 µM MCB-613 was shown to selectively and dose dependently induce paraptosis in a variety of cancer cells in vitro but not in normal cells.{29318} At 20 mg/kg, MCB-613 was also shown to inhibit tumor growth in an MCF-7 breast cancer xenograft model in mice.{29318}
Brand:CaymanSKU:-Available on backorder
The peroxisome proliferator-activated receptor-γ (PPARγ) is the nuclear receptor responsible for transducing the therapeutic activity of the thiazolidinediones (TZDs), a group of structurally related synthetic agonists with antidiabetic actions in vivo.{7575,8930} Rosiglitazone (BRL49653) is a prototypical TZD and has served as a reference compound for this class.{8461} MCC-555 is a structural homolog of rosiglitazone and the other TZDs. MCC-555 binds with about 1/10 the affinity of rosiglitazone to PPARγ.{7413} Despite this, MCC-555 is a more potent antidiabetic agent in whole animal experiments than rosiglitazone and several other prototypic TZDs; the ED50 value in these experiments was 2.7 mg/kg for MCC-555 compared with 7.1 mg/kg for rosiglitazone. MCC-555 is therefore a unique new member of the TZD class and may be useful in differentiating some of the multiple activities attributed to this class of compounds.
Brand:CaymanSKU:70735 - 1 mgAvailable on backorder
The peroxisome proliferator-activated receptor-γ (PPARγ) is the nuclear receptor responsible for transducing the therapeutic activity of the thiazolidinediones (TZDs), a group of structurally related synthetic agonists with antidiabetic actions in vivo.{7575,8930} Rosiglitazone (BRL49653) is a prototypical TZD and has served as a reference compound for this class.{8461} MCC-555 is a structural homolog of rosiglitazone and the other TZDs. MCC-555 binds with about 1/10 the affinity of rosiglitazone to PPARγ.{7413} Despite this, MCC-555 is a more potent antidiabetic agent in whole animal experiments than rosiglitazone and several other prototypic TZDs; the ED50 value in these experiments was 2.7 mg/kg for MCC-555 compared with 7.1 mg/kg for rosiglitazone. MCC-555 is therefore a unique new member of the TZD class and may be useful in differentiating some of the multiple activities attributed to this class of compounds.
Brand:CaymanSKU:70735 - 10 mgAvailable on backorder
The peroxisome proliferator-activated receptor-γ (PPARγ) is the nuclear receptor responsible for transducing the therapeutic activity of the thiazolidinediones (TZDs), a group of structurally related synthetic agonists with antidiabetic actions in vivo.{7575,8930} Rosiglitazone (BRL49653) is a prototypical TZD and has served as a reference compound for this class.{8461} MCC-555 is a structural homolog of rosiglitazone and the other TZDs. MCC-555 binds with about 1/10 the affinity of rosiglitazone to PPARγ.{7413} Despite this, MCC-555 is a more potent antidiabetic agent in whole animal experiments than rosiglitazone and several other prototypic TZDs; the ED50 value in these experiments was 2.7 mg/kg for MCC-555 compared with 7.1 mg/kg for rosiglitazone. MCC-555 is therefore a unique new member of the TZD class and may be useful in differentiating some of the multiple activities attributed to this class of compounds.
Brand:CaymanSKU:70735 - 25 mgAvailable on backorder
The peroxisome proliferator-activated receptor-γ (PPARγ) is the nuclear receptor responsible for transducing the therapeutic activity of the thiazolidinediones (TZDs), a group of structurally related synthetic agonists with antidiabetic actions in vivo.{7575,8930} Rosiglitazone (BRL49653) is a prototypical TZD and has served as a reference compound for this class.{8461} MCC-555 is a structural homolog of rosiglitazone and the other TZDs. MCC-555 binds with about 1/10 the affinity of rosiglitazone to PPARγ.{7413} Despite this, MCC-555 is a more potent antidiabetic agent in whole animal experiments than rosiglitazone and several other prototypic TZDs; the ED50 value in these experiments was 2.7 mg/kg for MCC-555 compared with 7.1 mg/kg for rosiglitazone. MCC-555 is therefore a unique new member of the TZD class and may be useful in differentiating some of the multiple activities attributed to this class of compounds.
Brand:CaymanSKU:70735 - 5 mgAvailable on backorder
NOD-like receptor (NLR) pyrin domain-containing protein 3 (NLRP3) senses pathogen-derived, environmental, and host-derived factors and initiates the formation of inflammasomes, complexes involved in complex diseases including multiple sclerosis, type 2 diabetes, Alzheimer’s disease, and atherosclerosis.{28326} MCC950 is a selective inhibitor of NLRP3, blocking the release of IL-1β in macrophages primed with LPS and activated with ATP or nigericin (IC50 = 7.5 nM).{28329} It does not inhibit NLRC4, AIM2, TLR2 signaling, or priming of NLRP3. MCC950 prevents oligomerization of apoptosis-associated speck-like protein containing a CARD (ASC) in cells stimulated with LPS and nigericin.{28329} MCC-950 is active in vivo, blocking the production of IL-1β and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome.{28329} It is also active in ex vivo samples from individuals with Muckle-Wells syndrome.
Brand:CaymanSKU:-Available on backorder
NOD-like receptor (NLR) pyrin domain-containing protein 3 (NLRP3) senses pathogen-derived, environmental, and host-derived factors and initiates the formation of inflammasomes, complexes involved in complex diseases including multiple sclerosis, type 2 diabetes, Alzheimer’s disease, and atherosclerosis.{28326} MCC950 is a selective inhibitor of NLRP3, blocking the release of IL-1β in macrophages primed with LPS and activated with ATP or nigericin (IC50 = 7.5 nM).{28329} It does not inhibit NLRC4, AIM2, TLR2 signaling, or priming of NLRP3. MCC950 prevents oligomerization of apoptosis-associated speck-like protein containing a CARD (ASC) in cells stimulated with LPS and nigericin.{28329} MCC-950 is active in vivo, blocking the production of IL-1β and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome.{28329} It is also active in ex vivo samples from individuals with Muckle-Wells syndrome.
Brand:CaymanSKU:-Available on backorder
NOD-like receptor (NLR) pyrin domain-containing protein 3 (NLRP3) senses pathogen-derived, environmental, and host-derived factors and initiates the formation of inflammasomes, complexes involved in complex diseases including multiple sclerosis, type 2 diabetes, Alzheimer’s disease, and atherosclerosis.{28326} MCC950 is a selective inhibitor of NLRP3, blocking the release of IL-1β in macrophages primed with LPS and activated with ATP or nigericin (IC50 = 7.5 nM).{28329} It does not inhibit NLRC4, AIM2, TLR2 signaling, or priming of NLRP3. MCC950 prevents oligomerization of apoptosis-associated speck-like protein containing a CARD (ASC) in cells stimulated with LPS and nigericin.{28329} MCC-950 is active in vivo, blocking the production of IL-1β and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome.{28329} It is also active in ex vivo samples from individuals with Muckle-Wells syndrome.
Brand:CaymanSKU:-Available on backorder
NOD-like receptor (NLR) pyrin domain-containing protein 3 (NLRP3) senses pathogen-derived, environmental, and host-derived factors and initiates the formation of inflammasomes, complexes involved in complex diseases including multiple sclerosis, type 2 diabetes, Alzheimer’s disease, and atherosclerosis.{28326} MCC950 is a selective inhibitor of NLRP3, blocking the release of IL-1β in macrophages primed with LPS and activated with ATP or nigericin (IC50 = 7.5 nM).{28329} It does not inhibit NLRC4, AIM2, TLR2 signaling, or priming of NLRP3. MCC950 prevents oligomerization of apoptosis-associated speck-like protein containing a CARD (ASC) in cells stimulated with LPS and nigericin.{28329} MCC-950 is active in vivo, blocking the production of IL-1β and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome.{28329} It is also active in ex vivo samples from individuals with Muckle-Wells syndrome.
Brand:CaymanSKU:-Available on backorder
MCHB-1 is a potent agonist of the human cannabinoid 2 (CB2) receptor (EC50 = 0.52 nM) that shows high selectivity for CB2 over CB1 (Kis = 3.7 and 110 nM, respectively).{21225} Similar benzimidazole compounds significantly reduce peripheral pain with reduced central nervous system side effects in mice.{21221}
Brand:CaymanSKU:9001949 - 1 mgAvailable on backorder
MCHB-1 is a potent agonist of the human cannabinoid 2 (CB2) receptor (EC50 = 0.52 nM) that shows high selectivity for CB2 over CB1 (Kis = 3.7 and 110 nM, respectively).{21225} Similar benzimidazole compounds significantly reduce peripheral pain with reduced central nervous system side effects in mice.{21221}
Brand:CaymanSKU:9001949 - 10 mgAvailable on backorder
MCHB-1 is a potent agonist of the human cannabinoid 2 (CB2) receptor (EC50 = 0.52 nM) that shows high selectivity for CB2 over CB1 (Kis = 3.7 and 110 nM, respectively).{21225} Similar benzimidazole compounds significantly reduce peripheral pain with reduced central nervous system side effects in mice.{21221}
Brand:CaymanSKU:9001949 - 5 mgAvailable on backorder
MCI-186 is a free radical scavenger with diverse protective effects in vivo. Most notably, it reduces damage due to ischemia-reperfusion injury in lung, liver, and brain in animal models of transplant, infection, traumatic brain injury, and stroke.{18271,18273,18270,18272} MCI-186 provides these protective effects, at least in part, by reducing reactive oxygen species, inhibiting apoptosis, and blocking nonenzymatic peroxidation and lipoxygenase activity.{18270,18274,18275}
Brand:CaymanSKU:- MCI-186 is a free radical scavenger with diverse protective effects in vivo. Most notably, it reduces damage due to ischemia-reperfusion injury in lung, liver, and brain in animal models of transplant, infection, traumatic brain injury, and stroke.{18271,18273,18270,18272} MCI-186 provides these protective effects, at least in part, by reducing reactive oxygen species, inhibiting apoptosis, and blocking nonenzymatic peroxidation and lipoxygenase activity.{18270,18274,18275}
Brand:CaymanSKU:- MCI-186 is a free radical scavenger with diverse protective effects in vivo. Most notably, it reduces damage due to ischemia-reperfusion injury in lung, liver, and brain in animal models of transplant, infection, traumatic brain injury, and stroke.{18271,18273,18270,18272} MCI-186 provides these protective effects, at least in part, by reducing reactive oxygen species, inhibiting apoptosis, and blocking nonenzymatic peroxidation and lipoxygenase activity.{18270,18274,18275}
Brand:CaymanSKU:-
MCLA is a Cypridina luciferin analog that is used to detect superoxide generated by activated leukocytes and macrophages.{30234} It emits chemiluminescence near 654 nm by reaction with superoxide or singlet oxygen.{30234}
Brand:CaymanSKU:-Available on backorder
MCLA is a Cypridina luciferin analog that is used to detect superoxide generated by activated leukocytes and macrophages.{30234} It emits chemiluminescence near 654 nm by reaction with superoxide or singlet oxygen.{30234}
Brand:CaymanSKU:-Available on backorder
MCLA is a Cypridina luciferin analog that is used to detect superoxide generated by activated leukocytes and macrophages.{30234} It emits chemiluminescence near 654 nm by reaction with superoxide or singlet oxygen.{30234}
Brand:CaymanSKU:-Available on backorder
McNA343 is a partial agonist of muscarinic acetylcholine receptors (Kis = 5, 1, 5, 0.2, and 7.6 µM for M1-5 receptors, respectively, in radioligand binding assays).{56099} It induces contraction of isolated human umbilical veins (EC50 = 1.23 µM), an effect that can be reversed by various M1 muscarinic receptor selective antagonists. McNA343 also inhibits forskolin-induced cAMP production in CHO cells expressing M1 or M4 receptors, as well as phosphatidylinositol hydrolysis in CHO-K1 cells expressing M3 receptors and CHO cells expressing M5 receptors. Intrathecal administration of McNA343 inhibits compulsive hindlimb neck-scratching behavior induced by 5’-guanidinonaltrindole (GNTI) in mice. It has nootropic activity, enhancing spontaneous working memory in the Y maze in wild-type mice, and it reverses learning and memory impairments induced by bulbectomy in mice in a passive avoidance test.
Brand:CaymanSKU:30961 - 10 mgAvailable on backorder
McNA343 is a partial agonist of muscarinic acetylcholine receptors (Kis = 5, 1, 5, 0.2, and 7.6 µM for M1-5 receptors, respectively, in radioligand binding assays).{56099} It induces contraction of isolated human umbilical veins (EC50 = 1.23 µM), an effect that can be reversed by various M1 muscarinic receptor selective antagonists. McNA343 also inhibits forskolin-induced cAMP production in CHO cells expressing M1 or M4 receptors, as well as phosphatidylinositol hydrolysis in CHO-K1 cells expressing M3 receptors and CHO cells expressing M5 receptors. Intrathecal administration of McNA343 inhibits compulsive hindlimb neck-scratching behavior induced by 5’-guanidinonaltrindole (GNTI) in mice. It has nootropic activity, enhancing spontaneous working memory in the Y maze in wild-type mice, and it reverses learning and memory impairments induced by bulbectomy in mice in a passive avoidance test.
Brand:CaymanSKU:30961 - 25 mgAvailable on backorder
McNA343 is a partial agonist of muscarinic acetylcholine receptors (Kis = 5, 1, 5, 0.2, and 7.6 µM for M1-5 receptors, respectively, in radioligand binding assays).{56099} It induces contraction of isolated human umbilical veins (EC50 = 1.23 µM), an effect that can be reversed by various M1 muscarinic receptor selective antagonists. McNA343 also inhibits forskolin-induced cAMP production in CHO cells expressing M1 or M4 receptors, as well as phosphatidylinositol hydrolysis in CHO-K1 cells expressing M3 receptors and CHO cells expressing M5 receptors. Intrathecal administration of McNA343 inhibits compulsive hindlimb neck-scratching behavior induced by 5’-guanidinonaltrindole (GNTI) in mice. It has nootropic activity, enhancing spontaneous working memory in the Y maze in wild-type mice, and it reverses learning and memory impairments induced by bulbectomy in mice in a passive avoidance test.
Brand:CaymanSKU:30961 - 50 mgAvailable on backorder
The nociceptin/orphanin FQ peptide (NOP, ORL1, or OP4) receptor is a member of the opioid family of receptors that integrates the emotional components of anxiety, fear, and stress. MCOPPB is a potent agonist for the NOP receptor (pKi = 10.1, EC50 = 0.39 nM) with 12-, 270-, and >1,000-fold selectivity over the μ-, κ-, and δ-opioid receptors.{22070,22071} In rodents, MCOPPB at 10 mg/kg, p.o. produces potent anxiolytic effects, without inhibiting memory or motor function or inducing sedative side effects.{22070} This product is intended for research purposes only.
Brand:CaymanSKU:12037 - 1 mgAvailable on backorder
The nociceptin/orphanin FQ peptide (NOP, ORL1, or OP4) receptor is a member of the opioid family of receptors that integrates the emotional components of anxiety, fear, and stress. MCOPPB is a potent agonist for the NOP receptor (pKi = 10.1, EC50 = 0.39 nM) with 12-, 270-, and >1,000-fold selectivity over the μ-, κ-, and δ-opioid receptors.{22070,22071} In rodents, MCOPPB at 10 mg/kg, p.o. produces potent anxiolytic effects, without inhibiting memory or motor function or inducing sedative side effects.{22070} This product is intended for research purposes only.
Brand:CaymanSKU:12037 - 10 mgAvailable on backorder
The nociceptin/orphanin FQ peptide (NOP, ORL1, or OP4) receptor is a member of the opioid family of receptors that integrates the emotional components of anxiety, fear, and stress. MCOPPB is a potent agonist for the NOP receptor (pKi = 10.1, EC50 = 0.39 nM) with 12-, 270-, and >1,000-fold selectivity over the μ-, κ-, and δ-opioid receptors.{22070,22071} In rodents, MCOPPB at 10 mg/kg, p.o. produces potent anxiolytic effects, without inhibiting memory or motor function or inducing sedative side effects.{22070} This product is intended for research purposes only.
Brand:CaymanSKU:12037 - 5 mgAvailable on backorder
Maresin conjugates in tissue regeneration 1 (MCTR1) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid (DHA; Item No. 90310) in macrophages at the site of inflammation.{29715,33727} DHA is oxidized to maresin 1 (MaR1; Item No. 10878), which is then converted to MCTR1 by glutathione S-transferase Mu 4 or leukotriene C4 synthase.{27629,33713,27956} MCTR1 accelerates tissue regeneration in planaria (1 and 100 nM).{33727} Pretreatment with MCTR1 (50 ng/mouse, i.p.) prior to E. coli administration reduces neutrophil infiltration, shortens the inflammatory resolution period, and increases phagocytosis of E. coli by macrophages.{33727} When administered at a dose of 100 ng 12h post E. coli infection in a mouse model of peritonitis, MCTR1 reduces the amount of eicosanoids in the exudate.
Brand:CaymanSKU:-Out of stock
Maresin conjugates in tissue regeneration 1 (MCTR1) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid (DHA; Item No. 90310) in macrophages at the site of inflammation.{29715,33727} DHA is oxidized to maresin 1 (MaR1; Item No. 10878), which is then converted to MCTR1 by glutathione S-transferase Mu 4 or leukotriene C4 synthase.{27629,33713,27956} MCTR1 accelerates tissue regeneration in planaria (1 and 100 nM).{33727} Pretreatment with MCTR1 (50 ng/mouse, i.p.) prior to E. coli administration reduces neutrophil infiltration, shortens the inflammatory resolution period, and increases phagocytosis of E. coli by macrophages.{33727} When administered at a dose of 100 ng 12h post E. coli infection in a mouse model of peritonitis, MCTR1 reduces the amount of eicosanoids in the exudate.
Brand:CaymanSKU:-Out of stock
Maresin conjugates in tissue regeneration 1 (MCTR1) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid (DHA; Item No. 90310) in macrophages at the site of inflammation.{29715,33727} DHA is oxidized to maresin 1 (MaR1; Item No. 10878), which is then converted to MCTR1 by glutathione S-transferase Mu 4 or leukotriene C4 synthase.{27629,33713,27956} MCTR1 accelerates tissue regeneration in planaria (1 and 100 nM).{33727} Pretreatment with MCTR1 (50 ng/mouse, i.p.) prior to E. coli administration reduces neutrophil infiltration, shortens the inflammatory resolution period, and increases phagocytosis of E. coli by macrophages.{33727} When administered at a dose of 100 ng 12h post E. coli infection in a mouse model of peritonitis, MCTR1 reduces the amount of eicosanoids in the exudate.
Brand:CaymanSKU:-Out of stock
Maresin conjugates in tissue regeneration 1 (MCTR1) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid (DHA; Item No. 90310) in macrophages at the site of inflammation.{29715,33727} DHA is oxidized to maresin 1 (MaR1; Item No. 10878), which is then converted to MCTR1 by glutathione S-transferase Mu 4 or leukotriene C4 synthase.{27629,33713,27956} MCTR1 accelerates tissue regeneration in planaria (1 and 100 nM).{33727} Pretreatment with MCTR1 (50 ng/mouse, i.p.) prior to E. coli administration reduces neutrophil infiltration, shortens the inflammatory resolution period, and increases phagocytosis of E. coli by macrophages.{33727} When administered at a dose of 100 ng 12h post E. coli infection in a mouse model of peritonitis, MCTR1 reduces the amount of eicosanoids in the exudate.
Brand:CaymanSKU:-Out of stock
Maresin conjugates in tissue regeneration 2 (MCTR2) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid (DHA; Item No. 90310) in macrophages at the site of inflammation.{29715,33727} DHA is oxidized to maresin 1 (MaR1; Item No. 10878), which is converted to MCTR1 (Item No. 17007) by glutathione S-transferase Mu 4 or leukotriene C4 synthase then to MCTR2 by γ-glutamyl transferase.{33713} MCTR2 accelerates tissue regeneration in planaria (1 and 100 nM).{33727} Pretreatment with MCTR2 prior to E. coli administration reduces neutrophil infiltration, shortens the inflammatory resolution period, and increases phagocytosis of E. coli by macrophages.{33727} When administered at a dose of 100 ng 12h post E. coli infection in a mouse model of peritonitis, MCTR2 selectively reduced the amount of the eicosanoids PGD2 (Item No. 12010) and PGF2α (Item No. 16010) in the exudate.{33727}
Brand:CaymanSKU:-Out of stock
Maresin conjugates in tissue regeneration 2 (MCTR2) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid (DHA; Item No. 90310) in macrophages at the site of inflammation.{29715,33727} DHA is oxidized to maresin 1 (MaR1; Item No. 10878), which is converted to MCTR1 (Item No. 17007) by glutathione S-transferase Mu 4 or leukotriene C4 synthase then to MCTR2 by γ-glutamyl transferase.{33713} MCTR2 accelerates tissue regeneration in planaria (1 and 100 nM).{33727} Pretreatment with MCTR2 prior to E. coli administration reduces neutrophil infiltration, shortens the inflammatory resolution period, and increases phagocytosis of E. coli by macrophages.{33727} When administered at a dose of 100 ng 12h post E. coli infection in a mouse model of peritonitis, MCTR2 selectively reduced the amount of the eicosanoids PGD2 (Item No. 12010) and PGF2α (Item No. 16010) in the exudate.{33727}
Brand:CaymanSKU:-Out of stock
Maresin conjugates in tissue regeneration 2 (MCTR2) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid (DHA; Item No. 90310) in macrophages at the site of inflammation.{29715,33727} DHA is oxidized to maresin 1 (MaR1; Item No. 10878), which is converted to MCTR1 (Item No. 17007) by glutathione S-transferase Mu 4 or leukotriene C4 synthase then to MCTR2 by γ-glutamyl transferase.{33713} MCTR2 accelerates tissue regeneration in planaria (1 and 100 nM).{33727} Pretreatment with MCTR2 prior to E. coli administration reduces neutrophil infiltration, shortens the inflammatory resolution period, and increases phagocytosis of E. coli by macrophages.{33727} When administered at a dose of 100 ng 12h post E. coli infection in a mouse model of peritonitis, MCTR2 selectively reduced the amount of the eicosanoids PGD2 (Item No. 12010) and PGF2α (Item No. 16010) in the exudate.{33727}
Brand:CaymanSKU:-Out of stock
Maresin conjugates in tissue regeneration 2 (MCTR2) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid (DHA; Item No. 90310) in macrophages at the site of inflammation.{29715,33727} DHA is oxidized to maresin 1 (MaR1; Item No. 10878), which is converted to MCTR1 (Item No. 17007) by glutathione S-transferase Mu 4 or leukotriene C4 synthase then to MCTR2 by γ-glutamyl transferase.{33713} MCTR2 accelerates tissue regeneration in planaria (1 and 100 nM).{33727} Pretreatment with MCTR2 prior to E. coli administration reduces neutrophil infiltration, shortens the inflammatory resolution period, and increases phagocytosis of E. coli by macrophages.{33727} When administered at a dose of 100 ng 12h post E. coli infection in a mouse model of peritonitis, MCTR2 selectively reduced the amount of the eicosanoids PGD2 (Item No. 12010) and PGF2α (Item No. 16010) in the exudate.{33727}
Brand:CaymanSKU:-Out of stock
Maresin conjugates in tissue regeneration 3 (MCTR3) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid (DHA; Item No. 90310) in macrophages.{29715,33727} DHA is oxidized to maresin 1 (MaR1; Item No. 10878), which is converted to MCTR1 (Item No. 17007) by glutathione S-transferase Mu 4 or leukotriene C4 synthase, then to MCTR2 (Item No. 17008) by γ-glutamyl transferase, and to MCTR3 by dipeptidase.{33713} MCTR3 accelerates tissue regeneration in planaria (1 and 100 nM) approximately as potently as MCTR2 and more potently than MCTR1.{33727} Pretreatment with MCTR3 prior to E. coli administration in mice reduces neutrophil infiltration, shortens the inflammatory resolution period, and increases phagocytosis of E. coli by macrophages. When administered at a dose of 100 ng 12h post E. coli infection in a mouse model of peritonitis, MCTR3 selectively reduces the amount of the eicosanoids PGD2 (Item No. 12010), PGE2 (Item No. 14010), PGF2α (Item No. 16010), and TXB2 (Item No. 19030) in the exudate.
Brand:CaymanSKU:-Available on backorder
Maresin conjugates in tissue regeneration 3 (MCTR3) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid (DHA; Item No. 90310) in macrophages.{29715,33727} DHA is oxidized to maresin 1 (MaR1; Item No. 10878), which is converted to MCTR1 (Item No. 17007) by glutathione S-transferase Mu 4 or leukotriene C4 synthase, then to MCTR2 (Item No. 17008) by γ-glutamyl transferase, and to MCTR3 by dipeptidase.{33713} MCTR3 accelerates tissue regeneration in planaria (1 and 100 nM) approximately as potently as MCTR2 and more potently than MCTR1.{33727} Pretreatment with MCTR3 prior to E. coli administration in mice reduces neutrophil infiltration, shortens the inflammatory resolution period, and increases phagocytosis of E. coli by macrophages. When administered at a dose of 100 ng 12h post E. coli infection in a mouse model of peritonitis, MCTR3 selectively reduces the amount of the eicosanoids PGD2 (Item No. 12010), PGE2 (Item No. 14010), PGF2α (Item No. 16010), and TXB2 (Item No. 19030) in the exudate.
Brand:CaymanSKU:-Available on backorder
Maresin conjugates in tissue regeneration 3 (MCTR3) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid (DHA; Item No. 90310) in macrophages.{29715,33727} DHA is oxidized to maresin 1 (MaR1; Item No. 10878), which is converted to MCTR1 (Item No. 17007) by glutathione S-transferase Mu 4 or leukotriene C4 synthase, then to MCTR2 (Item No. 17008) by γ-glutamyl transferase, and to MCTR3 by dipeptidase.{33713} MCTR3 accelerates tissue regeneration in planaria (1 and 100 nM) approximately as potently as MCTR2 and more potently than MCTR1.{33727} Pretreatment with MCTR3 prior to E. coli administration in mice reduces neutrophil infiltration, shortens the inflammatory resolution period, and increases phagocytosis of E. coli by macrophages. When administered at a dose of 100 ng 12h post E. coli infection in a mouse model of peritonitis, MCTR3 selectively reduces the amount of the eicosanoids PGD2 (Item No. 12010), PGE2 (Item No. 14010), PGF2α (Item No. 16010), and TXB2 (Item No. 19030) in the exudate.
Brand:CaymanSKU:-Available on backorder
Maresin conjugates in tissue regeneration 3 (MCTR3) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid (DHA; Item No. 90310) in macrophages.{29715,33727} DHA is oxidized to maresin 1 (MaR1; Item No. 10878), which is converted to MCTR1 (Item No. 17007) by glutathione S-transferase Mu 4 or leukotriene C4 synthase, then to MCTR2 (Item No. 17008) by γ-glutamyl transferase, and to MCTR3 by dipeptidase.{33713} MCTR3 accelerates tissue regeneration in planaria (1 and 100 nM) approximately as potently as MCTR2 and more potently than MCTR1.{33727} Pretreatment with MCTR3 prior to E. coli administration in mice reduces neutrophil infiltration, shortens the inflammatory resolution period, and increases phagocytosis of E. coli by macrophages. When administered at a dose of 100 ng 12h post E. coli infection in a mouse model of peritonitis, MCTR3 selectively reduces the amount of the eicosanoids PGD2 (Item No. 12010), PGE2 (Item No. 14010), PGF2α (Item No. 16010), and TXB2 (Item No. 19030) in the exudate.
Brand:CaymanSKU:-Available on backorder
MD001 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ.{43732} It binds to PPARα and PPARγ (Kds = 9.55 and 0.14 μM, respectively) but does not bind to PPARβ/δ at concentrations up to 500 μM. It increases transcriptional activity of PPARα and PPARγ in a cell-based luciferase reporter assay when used at a concentration of 10 μM. MD001 (10 μM) increases expression of PPARα, PPARγ, and retinoid X receptor (RXR), as well as PPARα and PPARγ target genes, in HepG2 cells. It increases glucose consumption as well as expression of GLUT2 and GLUT4 in HepG2 and 3T3-L1 cells, respectively, in a concentration-dependent manner. MD001 (20 mg/kg) decreases levels of glucose, insulin, free fatty acids, triglycerides, LDL, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in blood and reduces the size and number of hepatic lipid droplets in diabetic db/db mice.
Brand:CaymanSKU:27443 - 1 mgAvailable on backorder
MD001 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ.{43732} It binds to PPARα and PPARγ (Kds = 9.55 and 0.14 μM, respectively) but does not bind to PPARβ/δ at concentrations up to 500 μM. It increases transcriptional activity of PPARα and PPARγ in a cell-based luciferase reporter assay when used at a concentration of 10 μM. MD001 (10 μM) increases expression of PPARα, PPARγ, and retinoid X receptor (RXR), as well as PPARα and PPARγ target genes, in HepG2 cells. It increases glucose consumption as well as expression of GLUT2 and GLUT4 in HepG2 and 3T3-L1 cells, respectively, in a concentration-dependent manner. MD001 (20 mg/kg) decreases levels of glucose, insulin, free fatty acids, triglycerides, LDL, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in blood and reduces the size and number of hepatic lipid droplets in diabetic db/db mice.
Brand:CaymanSKU:27443 - 10 mgAvailable on backorder
MD001 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ.{43732} It binds to PPARα and PPARγ (Kds = 9.55 and 0.14 μM, respectively) but does not bind to PPARβ/δ at concentrations up to 500 μM. It increases transcriptional activity of PPARα and PPARγ in a cell-based luciferase reporter assay when used at a concentration of 10 μM. MD001 (10 μM) increases expression of PPARα, PPARγ, and retinoid X receptor (RXR), as well as PPARα and PPARγ target genes, in HepG2 cells. It increases glucose consumption as well as expression of GLUT2 and GLUT4 in HepG2 and 3T3-L1 cells, respectively, in a concentration-dependent manner. MD001 (20 mg/kg) decreases levels of glucose, insulin, free fatty acids, triglycerides, LDL, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in blood and reduces the size and number of hepatic lipid droplets in diabetic db/db mice.
Brand:CaymanSKU:27443 - 5 mgAvailable on backorder
MDA 19 is a selective agonist of the human peripheral cannabinoid (CB2) receptor, with an EC50 value for activation (63.4 nM) that is 14-fold lower than that for central cannabinoid (CB1) activation (EC50 = 867 nM).{18383} Surprisingly, it acts as an inverse agonist at the rat CB2 receptor in cell-based functional assays.{18533} MDA19 attenuates tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and in CB2+/+ mice but not in CB2-/- mice, indicating that CB2 receptors mediated the effects of MDA19.{18383,18533} These effects of MDA 19 are blocked by the selective CB2 antagonist AM630.{18383}
Brand:CaymanSKU:10563 - 1 mgAvailable on backorder
MDA 19 is a selective agonist of the human peripheral cannabinoid (CB2) receptor, with an EC50 value for activation (63.4 nM) that is 14-fold lower than that for central cannabinoid (CB1) activation (EC50 = 867 nM).{18383} Surprisingly, it acts as an inverse agonist at the rat CB2 receptor in cell-based functional assays.{18533} MDA19 attenuates tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and in CB2+/+ mice but not in CB2-/- mice, indicating that CB2 receptors mediated the effects of MDA19.{18383,18533} These effects of MDA 19 are blocked by the selective CB2 antagonist AM630.{18383}
Brand:CaymanSKU:10563 - 10 mgAvailable on backorder
MDA 19 is a selective agonist of the human peripheral cannabinoid (CB2) receptor, with an EC50 value for activation (63.4 nM) that is 14-fold lower than that for central cannabinoid (CB1) activation (EC50 = 867 nM).{18383} Surprisingly, it acts as an inverse agonist at the rat CB2 receptor in cell-based functional assays.{18533} MDA19 attenuates tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and in CB2+/+ mice but not in CB2-/- mice, indicating that CB2 receptors mediated the effects of MDA19.{18383,18533} These effects of MDA 19 are blocked by the selective CB2 antagonist AM630.{18383}
Brand:CaymanSKU:10563 - 5 mgAvailable on backorder
MDA 19 is a selective agonist of the human peripheral cannabinoid (CB2) receptor, with an EC50 value for activation (63.4 nM) that is 14-fold lower than that for central cannabinoid (CB1) activation (EC50 = 867 nM).{18383} Surprisingly, it acts as an inverse agonist at the rat CB2 receptor in cell-based functional assays.{18533} MDA19 attenuates tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and in CB2+/+ mice but not in CB2-/- mice, indicating that CB2 receptors mediated the effects of MDA19.{18383,18533} These effects of MDA 19 are blocked by the selective CB2 antagonist AM630.{18383}
Brand:CaymanSKU:10563 - 50 mgAvailable on backorder
MDA 77 is a selective inverse agonist of the human peripheral cannabinoid (CB2) receptor that demonstrates an EC50 value of 5.8 nM at CB2 and no activity at central cannabinoids (CB1) receptor in functional binding assays.{19491} The in vivo activity of this compound has not been reported.
Brand:CaymanSKU:10639 - 1 mgAvailable on backorder
MDA 77 is a selective inverse agonist of the human peripheral cannabinoid (CB2) receptor that demonstrates an EC50 value of 5.8 nM at CB2 and no activity at central cannabinoids (CB1) receptor in functional binding assays.{19491} The in vivo activity of this compound has not been reported.
Brand:CaymanSKU:10639 - 10 mgAvailable on backorder
MDA 77 is a selective inverse agonist of the human peripheral cannabinoid (CB2) receptor that demonstrates an EC50 value of 5.8 nM at CB2 and no activity at central cannabinoids (CB1) receptor in functional binding assays.{19491} The in vivo activity of this compound has not been reported.
Brand:CaymanSKU:10639 - 5 mgAvailable on backorder
MDA 77 is a selective inverse agonist of the human peripheral cannabinoid (CB2) receptor that demonstrates an EC50 value of 5.8 nM at CB2 and no activity at central cannabinoids (CB1) receptor in functional binding assays.{19491} The in vivo activity of this compound has not been reported.
Brand:CaymanSKU:10639 - 50 mgAvailable on backorder
MDAI is an indane analog of 3,4-(methylenedioxy)amphetamine (MDA), a psychoactive compound. In animal studies, MDAI effects are indistinguishable from 3,4-(methylenedioxy)methamphetamine (MDMA).{20175} While non-neurotoxic in animals when administered alone, MDAI produces significant serotonin neurotoxicity when given with dopaminergic agents.{20174} MDAI has potential for abuse; this product is intended for forensic purposes.
Brand:CaymanSKU:9001102 - 1 mgAvailable on backorder
MDAI is an indane analog of 3,4-(methylenedioxy)amphetamine (MDA), a psychoactive compound. In animal studies, MDAI effects are indistinguishable from 3,4-(methylenedioxy)methamphetamine (MDMA).{20175} While non-neurotoxic in animals when administered alone, MDAI produces significant serotonin neurotoxicity when given with dopaminergic agents.{20174} MDAI has potential for abuse; this product is intended for forensic purposes.
Brand:CaymanSKU:9001102 - 10 mgAvailable on backorder
MDAI is an indane analog of 3,4-(methylenedioxy)amphetamine (MDA), a psychoactive compound. In animal studies, MDAI effects are indistinguishable from 3,4-(methylenedioxy)methamphetamine (MDMA).{20175} While non-neurotoxic in animals when administered alone, MDAI produces significant serotonin neurotoxicity when given with dopaminergic agents.{20174} MDAI has potential for abuse; this product is intended for forensic purposes.
Brand:CaymanSKU:9001102 - 5 mgAvailable on backorder